SE513429C2 - Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer - Google Patents

Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer

Info

Publication number
SE513429C2
SE513429C2 SE9201719A SE9201719A SE513429C2 SE 513429 C2 SE513429 C2 SE 513429C2 SE 9201719 A SE9201719 A SE 9201719A SE 9201719 A SE9201719 A SE 9201719A SE 513429 C2 SE513429 C2 SE 513429C2
Authority
SE
Sweden
Prior art keywords
cells
serotonin
histamine
ifn
pharmaceutical composition
Prior art date
Application number
SE9201719A
Other languages
English (en)
Swedish (sv)
Other versions
SE9201719L (sv
SE9201719D0 (sv
Inventor
Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Syntello Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Inc filed Critical Syntello Inc
Priority to SE9201719A priority Critical patent/SE513429C2/sv
Publication of SE9201719D0 publication Critical patent/SE9201719D0/xx
Priority to JP6500471A priority patent/JP2888259B2/ja
Priority to AT93913731T priority patent/ATE192338T1/de
Priority to DK93913731T priority patent/DK0652768T3/da
Priority to ES93913731T priority patent/ES2147758T3/es
Priority to PT93913731T priority patent/PT652768E/pt
Priority to EP93913731A priority patent/EP0652768B1/de
Priority to AU43660/93A priority patent/AU672610C/en
Priority to DE69328558T priority patent/DE69328558T2/de
Priority to CA002136952A priority patent/CA2136952C/en
Priority to US08/374,787 priority patent/US5728378A/en
Priority to PCT/SE1993/000496 priority patent/WO1993024144A1/en
Publication of SE9201719L publication Critical patent/SE9201719L/xx
Priority to US09/033,110 priority patent/US6003516A/en
Priority to GR20000401579T priority patent/GR3033894T3/el
Publication of SE513429C2 publication Critical patent/SE513429C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9201719A 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer SE513429C2 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
PCT/SE1993/000496 WO1993024144A1 (en) 1992-06-03 1993-06-03 PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY
EP93913731A EP0652768B1 (de) 1992-06-03 1993-06-03 Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
DE69328558T DE69328558T2 (de) 1992-06-03 1993-06-03 Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
DK93913731T DK0652768T3 (da) 1992-06-03 1993-06-03 Præparat til aktivering af naturlige dræberceller (NK-celler), hvilket præparat indeholder interferon-alfa og histamin, ser
ES93913731T ES2147758T3 (es) 1992-06-03 1993-06-03 Preparacion sinergistica para la activacion de celulas destructoras naturales.
PT93913731T PT652768E (pt) 1992-06-03 1993-06-03 Preparacao para activar as celulas aniquiladoras naturais (celulas an) em que a referida preparacao contem interferao alfa e histamina serotonina ou substancias com a correspondente actividade receptorial
JP6500471A JP2888259B2 (ja) 1992-06-03 1993-06-03 インターフェロン−αとヒスタミン、セロトニンまたは相当するレセプター活性を有する物質とを含有するナチュラルキラー細胞（ＮＫ細胞）活性化用製剤
AU43660/93A AU672610C (en) 1992-06-03 1993-06-03 Preparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin or substances with corresponding receptor activity
AT93913731T ATE192338T1 (de) 1992-06-03 1993-06-03 Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen
CA002136952A CA2136952C (en) 1992-06-03 1993-06-03 Preparation for activation of natural killer cells (nk-cells), said preparation containing interferon-– and histamine, serotonin, amines or substances with corresponding receptor activity
US08/374,787 US5728378A (en) 1992-06-03 1993-06-03 Preparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin, amines or substances with corresponding receptor activity
US09/033,110 US6003516A (en) 1992-06-03 1998-03-02 Method for treatment of cancer and infectious disease
GR20000401579T GR3033894T3 (en) 1992-06-03 2000-07-05 Preparation for activation of natural killer cells (nk-cells), said preparation containing interferon-alpha and histamine, serotonin or substances with corresponding receptor activity.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer

Publications (3)

Publication Number Publication Date
SE9201719D0 SE9201719D0 (sv) 1992-06-03
SE9201719L SE9201719L (sv) 1993-12-04
SE513429C2 true SE513429C2 (sv) 2000-09-11

Family

ID=20386405

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9201719A SE513429C2 (sv) 1992-06-03 1992-06-03 Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer

Country Status (12)

Country Link
US (1) US5728378A (de)
EP (1) EP0652768B1 (de)
JP (1) JP2888259B2 (de)
AT (1) ATE192338T1 (de)
CA (1) CA2136952C (de)
DE (1) DE69328558T2 (de)
DK (1) DK0652768T3 (de)
ES (1) ES2147758T3 (de)
GR (1) GR3033894T3 (de)
PT (1) PT652768E (de)
SE (1) SE513429C2 (de)
WO (1) WO1993024144A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063373A (en) 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
US6003516A (en) * 1992-06-03 1999-12-21 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
EP0690715B1 (de) * 1993-03-26 2003-05-28 Beth Israel Hospital Association Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
JPH10504304A (ja) * 1994-08-08 1998-04-28 マキシム ファーマシューティカルズ，インコーポレイテッド ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
WO2000010600A2 (en) * 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
EP0998923A1 (de) * 1998-10-30 2000-05-10 Basf Aktiengesellschaft Verwendung von 5-HT7 Rezeptoragonisten zur Behandlung oder Vorbeugung von Ischämien
DE69939027D1 (de) 1998-12-23 2008-08-14 Maxim Pharm Inc Synthese von histamin-dihydrochlorid
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
KR20040058192A (ko) * 2001-10-19 2004-07-03 맥심 파마수티컬즈 인크. 간 질환 치료용으로서의 히스타민 용도
CN100563648C (zh) * 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
EP1712634A1 (de) * 2005-04-13 2006-10-18 Wittycell SAS Verfahren zur Auswahl von effizienten antigen präsentierenden Zellen und ihre Anwendung in der Regulation der Immunität
SG166716A1 (en) 2009-05-14 2010-12-29 Hsiehs Biotech Singapore Pte Ltd Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
CN115925920B (zh) * 2022-08-04 2023-07-25 瑞因细胞工程科技(广州)有限公司 一种基因增强型免疫细胞治疗肝硬化的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
EP0295317A1 (de) * 1987-06-16 1988-12-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Pharmazeutische Zusammensetzung zur Behandlung von Tumoren
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
ES2147758T3 (es) 2000-10-01
DK0652768T3 (da) 2000-08-07
AU672610B2 (en) 1996-10-10
SE9201719L (sv) 1993-12-04
JPH08502024A (ja) 1996-03-05
DE69328558D1 (de) 2000-06-08
WO1993024144A1 (en) 1993-12-09
DE69328558T2 (de) 2001-01-04
ATE192338T1 (de) 2000-05-15
PT652768E (pt) 2000-09-29
AU4366093A (en) 1993-12-30
US5728378A (en) 1998-03-17
CA2136952A1 (en) 1993-12-09
EP0652768B1 (de) 2000-05-03
CA2136952C (en) 2005-08-09
JP2888259B2 (ja) 1999-05-10
SE9201719D0 (sv) 1992-06-03
GR3033894T3 (en) 2000-11-30
EP0652768A1 (de) 1995-05-17

Similar Documents

Publication Publication Date Title
SE513429C2 (sv) Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
EP0493468B1 (de) Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten
US5932208A (en) Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
De Maeyer et al. Type I interferons
Vujanovic et al. Changes of liver-resident NK cells during liver regeneration in rats.
EP0107498A2 (de) Synergistische Humaninterferonaktivität
HU220105B (hu) Ribavirin alkalmazása TH1- és TH2- válaszreakció befolyásolására szolgáló készítmények előállítására
CN116018148A (zh) Nk细胞及其用于治疗微生物感染的用途
Ortaldo et al. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice
Kakumu et al. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon
US6155266A (en) Method for treatment of cancer and infectious disease
EP0295559B1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Tumoren
BORDEN et al. Biological and clinical effects of interferon-βser at two doses
Gastl et al. Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing
Richard et al. Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo
Dröge et al. Suppression of cytotoxic T lymphocyte activation by L-ornithine.
US6003516A (en) Method for treatment of cancer and infectious disease
AU672610C (en) Preparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin or substances with corresponding receptor activity
Hellstrand et al. A Cell‐to‐Cell Mediated Interaction Involving Monocytes and Non‐T/CD16+ Natural Killer (NK) Cells is Required for Histamine H2‐Receptor‐Mediated NK‐Cell Activation
Bhuiya et al. Interferon-α generation in mice responding to challenge with UV-inactivated herpes simplex virus
Randhawa et al. EFFECTS OF IMMUNOTHERAPY ON EXPERIMENTAL IMMUNODEFICIENCY-RELATED LYMPHOPROLIFERATIVE DISEASE1.
Hovi et al. Interferon affects the formation of adhesion plaques in human monocyte cultures
Takahashi et al. Suppression of liver regeneration resulting from intravenous injection of splenic glass adherent cells activated by poly I: C
Testi et al. Sequential metabolic events and morphological changes during in vivo large granular lymphocyte activation and proliferation
Shaw et al. 3′-Azido-3′-deoxythymidine inhibition of human lymphocyte cytolytic function in vitro

Legal Events

Date Code Title Description
NUG Patent has lapsed